Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06734130

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

A Phase IIA Study of Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Conditions Metastatic Castration Sensitive Prostate Cancer

Interventions Androgen Receptor Signal Inhibitor (ARSI) Docetaxel Luteinizing Hormone-Releasing Hormone (LHRH) analog

Updated 7 times since 2025 Last updated: Jan 20, 2026 Started: Jan 10, 2025 Primary completion: Nov 30, 2028 Completion: Nov 30, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Metastatic Castration Sensitive Prostate Cancer and is currently ongoing. H. Lee Moffitt Cancer Center and Research Institute leads this study, which shows 7 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Feb 2026 — Present [monthly]

Active Not Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Jul 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Apr 2025 — Jul 2025 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Feb 2025 — Apr 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Feb 2025 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

H. Lee Moffitt Cancer Center and Research Institute

Data source: H. Lee Moffitt Cancer Center and Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tampa, United States